Marietta, Georgia 30060

  • Hidradenitis Suppurativa

Purpose:

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).


Criteria:

Inclusion Criteria: - Have a diagnosis of HS for at least 6 months - Have HS lesions in at least 2 different anatomic areas - Have inadequate response or intolerance to a 28 day course of oral antibiotics - Have a total count of abscesses and inflammatory nodules greater than or equal to 4 - Agree to use a topical antiseptic daily - Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed Exclusion Criteria: - Have more than 20 draining fistulae - Have received any biologic medication (adalimumab, etc.) for the treatment of HS - Plan to use oral opioids for HS-related pain during the study - Uncontrolled depression or suicidal thoughts


NCT ID:

NCT04493502


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559
Email: ClinicalTrials.gov@lilly.com


Backup Contact:

N/A


Location Contact:

Marietta, Georgia 30060
United States

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 15, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.